Cargando…

Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil

Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial t...

Descripción completa

Detalles Bibliográficos
Autores principales: Camargo, Carlos Henrique, Yamada, Amanda Yaeko, de Souza, Andreia Rodrigues, Lima, Marisa de Jesus de Castro, Cunha, Marcos Paulo Vieira, Ferraro, Pedro Smith Pereira, Sacchi, Claudio Tavares, dos Santos, Marlon Benedito Nascimento, Campos, Karoline Rodrigues, Tiba-Casas, Monique Ribeiro, Freire, Maristela Pinheiro, Barretti, Pasqual
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384983/
https://www.ncbi.nlm.nih.gov/pubmed/37513765
http://dx.doi.org/10.3390/pathogens12070918
_version_ 1785081291937415168
author Camargo, Carlos Henrique
Yamada, Amanda Yaeko
de Souza, Andreia Rodrigues
Lima, Marisa de Jesus de Castro
Cunha, Marcos Paulo Vieira
Ferraro, Pedro Smith Pereira
Sacchi, Claudio Tavares
dos Santos, Marlon Benedito Nascimento
Campos, Karoline Rodrigues
Tiba-Casas, Monique Ribeiro
Freire, Maristela Pinheiro
Barretti, Pasqual
author_facet Camargo, Carlos Henrique
Yamada, Amanda Yaeko
de Souza, Andreia Rodrigues
Lima, Marisa de Jesus de Castro
Cunha, Marcos Paulo Vieira
Ferraro, Pedro Smith Pereira
Sacchi, Claudio Tavares
dos Santos, Marlon Benedito Nascimento
Campos, Karoline Rodrigues
Tiba-Casas, Monique Ribeiro
Freire, Maristela Pinheiro
Barretti, Pasqual
author_sort Camargo, Carlos Henrique
collection PubMed
description Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial therapy. Therefore, the in vitro evaluation of these drugs in contemporary isolates is warranted. We evaluated the antimicrobial susceptibility and genomic aspects of 119 clinical P. aeruginosa isolates from 24 different hospitals in Brazil in 2021–2022. Identification was performed via MALDI-TOF-MS, and antimicrobial susceptibility was identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing was carried out using NextSeq equipment. The most active drug was cefiderocol (100%), followed by ceftazidime–avibactam (94.1%), ceftolozane–tazobactam (92.4%), and imipenem–relebactam (81.5%). Imipenem susceptibility was detected in 59 isolates (49.6%), and the most active aminoglycoside was tobramycin, to which 99 (83.2%) isolates were susceptible. Seventy-one different sequence types (STs) were detected, including twelve new STs described herein. The acquired resistance genes bla(CTX-M-2) and bla(KPC-2) were identified in ten (8.4%) and two (1.7%) isolates, respectively. Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years.
format Online
Article
Text
id pubmed-10384983
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103849832023-07-30 Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil Camargo, Carlos Henrique Yamada, Amanda Yaeko de Souza, Andreia Rodrigues Lima, Marisa de Jesus de Castro Cunha, Marcos Paulo Vieira Ferraro, Pedro Smith Pereira Sacchi, Claudio Tavares dos Santos, Marlon Benedito Nascimento Campos, Karoline Rodrigues Tiba-Casas, Monique Ribeiro Freire, Maristela Pinheiro Barretti, Pasqual Pathogens Article Pseudomonas aeruginosa, an opportunistic pathogen causing infections in immunocompromised patients, usually shows pronounced antimicrobial resistance. In recent years, the frequency of carbapenemases in P. aeruginosa has decreased, which allows use of new beta-lactams/combinations in antimicrobial therapy. Therefore, the in vitro evaluation of these drugs in contemporary isolates is warranted. We evaluated the antimicrobial susceptibility and genomic aspects of 119 clinical P. aeruginosa isolates from 24 different hospitals in Brazil in 2021–2022. Identification was performed via MALDI-TOF-MS, and antimicrobial susceptibility was identified through broth microdilution, gradient tests, or disk diffusion. Whole-genome sequencing was carried out using NextSeq equipment. The most active drug was cefiderocol (100%), followed by ceftazidime–avibactam (94.1%), ceftolozane–tazobactam (92.4%), and imipenem–relebactam (81.5%). Imipenem susceptibility was detected in 59 isolates (49.6%), and the most active aminoglycoside was tobramycin, to which 99 (83.2%) isolates were susceptible. Seventy-one different sequence types (STs) were detected, including twelve new STs described herein. The acquired resistance genes bla(CTX-M-2) and bla(KPC-2) were identified in ten (8.4%) and two (1.7%) isolates, respectively. Several virulence genes (exoSTUY, toxA, aprA, lasA/B, plcH) were also identified. We found that new antimicrobials are effective against the diverse P. aeruginosa population that has been circulating in Brazilian hospitals in recent years. MDPI 2023-07-08 /pmc/articles/PMC10384983/ /pubmed/37513765 http://dx.doi.org/10.3390/pathogens12070918 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Camargo, Carlos Henrique
Yamada, Amanda Yaeko
de Souza, Andreia Rodrigues
Lima, Marisa de Jesus de Castro
Cunha, Marcos Paulo Vieira
Ferraro, Pedro Smith Pereira
Sacchi, Claudio Tavares
dos Santos, Marlon Benedito Nascimento
Campos, Karoline Rodrigues
Tiba-Casas, Monique Ribeiro
Freire, Maristela Pinheiro
Barretti, Pasqual
Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
title Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
title_full Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
title_fullStr Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
title_full_unstemmed Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
title_short Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil
title_sort genomics and antimicrobial susceptibility of clinical pseudomonas aeruginosa isolates from hospitals in brazil
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384983/
https://www.ncbi.nlm.nih.gov/pubmed/37513765
http://dx.doi.org/10.3390/pathogens12070918
work_keys_str_mv AT camargocarloshenrique genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT yamadaamandayaeko genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT desouzaandreiarodrigues genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT limamarisadejesusdecastro genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT cunhamarcospaulovieira genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT ferraropedrosmithpereira genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT sacchiclaudiotavares genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT dossantosmarlonbeneditonascimento genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT camposkarolinerodrigues genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT tibacasasmoniqueribeiro genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT freiremaristelapinheiro genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil
AT barrettipasqual genomicsandantimicrobialsusceptibilityofclinicalpseudomonasaeruginosaisolatesfromhospitalsinbrazil